Concord Biotech Limited (BOM:543960)
1,420.30
+87.10 (6.53%)
At close: Jul 31, 2026
Concord Biotech Revenue
Concord Biotech had revenue of 2.57B INR in the quarter ending June 30, 2026, with 26.23% growth. This brings the company's revenue in the last twelve months to 11.08B, down -6.72% year-over-year. In the fiscal year ending March 31, 2026, Concord Biotech had annual revenue of 10.55B, down -12.10%.
Revenue (ttm)
11.08B
Revenue Growth
-6.72%
P/S Ratio
13.41
Revenue / Employee
6.83M
Employees
1,624
Market Cap
148.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 10.55B | -1.45B | -12.10% |
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
Concord Biotech News
- Just now - Concord Biotech Quarterly report: Q1 2027 - Filings
- Just now - Concord Biotech Slides: Q1 2027 - Filings
- 2 months ago - Concord Biotech Transcript: Q4 25/26 - Transcripts
- 2 months ago - Concord Biotech Quarterly report: Q4 2026 - Filings
- 2 months ago - Concord Biotech Slides: Q4 2026 - Filings
- 2 months ago - Concord Biotech Annual report: Q4 2026 - Filings
- 6 months ago - Concord Biotech Transcript: Q3 25/26 - Transcripts
- 6 months ago - Concord Biotech Quarterly report: Q3 2026 - Filings